LEVELS OF INTESTINAL INFLAMMATION MARKERS AS A DIAGNOSTIC CRITERION FOR FORMING A RISK GROUP FOR IDENTIFICATION OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN ULCER COLIT

Stepanov Yu. M., Psareva I. V., Tatarchuk O. M., Zygalo E. V., Petishko O. P.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Aim. To determine the feasibility of using fecal markers of inflammation in patients with ulcerative colitis (UC) to form a risk group for the detection of excess small intestinal bacterial overgrowth (SIBO). Object and methods. A total of 52 patients with UC between the ages of 20 and 73 years were examined, among whom 26 were equally divided between women and men (50.0%). In all patients, SIBO was determined using a hydrogen breath test. Using enzyme immunoassay, the level of serum and feces α1-antitrypsin, the level of fecal calprotectin and fecal myeloperoxidase were determined. Results. SIBO was diagnosed in 63.5% of patients with UC. Moreover, with severe UC activity, patients with SIBO were 2.8 times higher than patients without SIBO (χ2 =8.69, p=0.0032). 1.5 times more often SIBO was detected with widespread colitis than with left-sided colitis and proctitis. Elevated levels of fecal markers of intestinal inflammation were combined with bacterial contamination of the small intestine. A direct correlation was established between the level of fecal myeloperoxidase and the detection rate of SIBO (r=0.74; p=0.04). The conclusion. The level of fecal myeloperoxidase of more than 4000 ng/g is a diagnostic criterion for the formation of a risk group for identifying SIBO in patients with UC (sensitivity 90.9%, specificity 84.0%).

ulcerative colitis, diagnosis, non-invasive markers of inflammation, small intestinal bacterial overgrowth.

1. Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94(7):1357-73. DOI: 10.1016/j.mayocp.2019.01.018
2. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769-78. DOI: 10.1016/S0140-6736(17)32448-0
3. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205-17. DOI: 10.1038/nrgastro.2015.34
4. Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019:100851. DOI: 10.1016/j.disamonth.2019.02.004
5. Langhorst J, Boone J, Lauche R, Rueffer A, Dobos G. Faecal lactoferrin, calprotectin, PMN-elastase, CRP, and white blood cell count as indicators for mucosal healing and clinical course of disease in patients with mild to moderate ulcerative colitis: Post hoc analysis of a prospective clinical trial. Journal of Crohn’s and Colitis. 2016;10(7):786-94. DOI: 10.1093/ecco-jcc/jjw044
6. Cioffi M, Rosa AD, Serao R, Picone I, Vietri MT. Laboratory markers in ulcerative colitis: Current insights and future advances. World J Gastrointest Pathophysiol. 2015;6(1):13-22. DOI: 10.4291/wjgp.v6.i1.13
7. Rao SSC, Bhagatwala J. Small intestinal bacterial overgrowth: clinical features and therapeutic management. Clin Transl Gastroenterol. 2019;10(10):e00078. DOI: 10.14309/ctg.0000000000000078
8. Cohen-Mekelburg S, Tafesh Z, Coburn E, Weg R, Malik N, Webb C, et al. Testing and treating small intestinal bacterial overgrowth reduces symptoms in patients with inflammatory bowel disease. Dig Dis Sci. 2018;63(9):2439-44. DOI: 10.1007/s10620-018-5109-1
9. Ní Chonchubhair HM, Bashir Y, Dobson M, Ryan BM, Duggan SN, Conlon KC. The prevalence of small intestinal bacterial overgrowth in nonsurgical patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI). Pancreatology. 2018 Jun;18(4):379-85. DOI:
10. 16/j. pan.2018.02.010 10. El Kurdi B, Babar S, El Iskandarani M, Bataineh A, Lerch MM, Young M, et al. Factors that affect prevalence of small intestinal bacterial overgrowth in chronic pancreatitis: a systematic review, meta-analysis, and meta-regression. Clin Transl Gastroenterol. 2019;10(9):e00072. DOI: 10.14309/ctg.0000000000000072
11. Wijarnpreecha K, Lou S, Watthanasuntorn K, Kroner PT, Cheungpasitporn W, Lukens FJ, et al. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019 Sep 16. DOI: 10.1097/ MEG.0000000000001541
12. Liu Chen Kiow J, Vincent C, Sidani S, Bouin M. High occurrence of small intestinal bacterial overgrowth in primary biliary cholangitis. Neurogastroenterol Motil. 2019 Nov;31(11):e13691. DOI: 10.1111/nmo.13691
13. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013;19(40):6911-8. DOI: 10.3748/wjg.v19.i40.6911
14. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272-84. DOI: 10.1016/j.jhep.2015.07.004
15. Rana SV, Sharma S, Kaur J, Prasad KK, Sinha SK, Kochhar R, et al. Relationship of cytokines, oxidative stress and GI motility with bacterial overgrowth in ulcerative colitis patients. J Crohns Colitis. 2014;8(8):859-65. DOI: 10.1016/j.crohns.2014.01.007
16. Marie I, Leroi AM, Menard JF, Levesque H, Quillard M, Ducrotte P. Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev. 2015 Jun;14(6):547-54. DOI: 10.1016/j.autrev.2015.01.018
17. Montalto M, Santoro L, Dalvai S, Curigliano V, D’Onofrio F, Scarpellini E, et al. Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. Dig Dis. 2008;26(2):183-6.
18. Fundarò C, Fantacci C, Ansuini V, Giorgio V, Filoni S, Barbaro F, et al. Fecal calprotectin concentration in children affected by SIBO. Eur Rev Med Pharmacol Sci. 2011 Nov;15(11):1328-35.

«Bulletin of problems biology and medicine» Issue 4 Part 2 (154), 2019 year, 204-207 pages, index UDK 616.34-002.44-008.87-078

10.29254/2077-4214-2019-4-2-154-204-207